Michael Oellerich - Concepedia

Author

Michael Oellerich

Also Known As

M OELLERICH, M Oellerich, M. OELLERICH, M. Oellerich, M. Oellerich,, MICHAEL OELLERICH, Mark Oellerich, Michael Oellerich, Netherlands Working Group, Oellerich M

524

Publications

16.8K

Citations

H-Index

235

Concepts

All Affiliations

University of Göttingen Medizinische Hochschule Hannover Universitätsmedizin Göttingen Heidelberg University University Hospital Heidelberg

About

Michael Oellerich is an author at University of Göttingen specializing in medicine, pharmacology, and clinical chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	112	5.6K
2	Health Sciences	13	19	410
3	Natural Sciences	11	12	568
4	Engineering	3	3	115
5	Public Health	1	1	34

Michael Oellerich

227

Publications

12.4K

Citations

H-Index

Page 1

	Year	Citations
Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference Pierre Wallemacq, Victor W. Armstrong, Merçè Brunet, Therapeutic Drug Monitoring Uniform DoseSolid Organ TransplantationTransplantation MedicineSurgeryPharmacotherapy	2009	453
The Pharmacokinetic-Pharmacodynamic Relationship for Total and Free Mycophenolic Acid in Pediatric Renal Transplant Recipients Lutz T. Weber, Maria Shipkova, Victor W. Armstrong, Journal of the American Society of Nephrology TransplantationKidney TransplantMycophenolic AcidMedicinePharmacokinetic-pharmacodynamic Relationship	2002	278
Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial Teun van Gelder, Hélio Tedesco‐Silva, Johan W. de Fijter, Transplantation	2008	273
Digital Droplet PCR for Rapid Quantification of Donor DNA in the Circulation of Transplant Recipients as a Potential Universal Biomarker of Graft Injury Julia Beck, Sarah Bierau, Stefan Balzer, Clinical Chemistry	2013	266
No Influence of the MDR-1 C3435T Polymorphism or a CYP3A4 Promoter Polymorphism (CYP3A4-V Allele) on Dose-adjusted Cyclosporin A Trough Concentrations or Rejection Incidence in Stable Renal Transplant Recipients Nicolas von Ahsen, Michael Richter, Clemens Grupp, Clinical Chemistry	2001	261
Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus Landry K. Kamdem, Frank Streit, Ulrich M. Zanger, Clinical Chemistry	2005	219
Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Lutz T. Weber, Maria Shipkova, T. Lamersdorf, Journal of the American Society of Nephrology Transplantation MedicinePharmacotherapyPharmacokineticsMycophenolate MofetilRenal Function	1998	218
Identification of glucoside and carboxyl‐linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil Maria Shipkova, Victor W. Armstrong, Eberhard Wieland, British Journal of Pharmacology	1999	211
Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study Michael Oellerich, Maria Shipkova, Thomas Asendorf, American Journal of Transplantation	2019	209
Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study Ekkehard Schütz, Anna Fischer, Julia Beck, PLoS Medicine	2017	203

Page 1